linjc16/ctgov huggingface dataset:
Preventing Depression Recurrence in Diabetes

Study Overview
=================
Brief Summary
-----------------
To study the effectiveness of sertraline (Zoloft) in treating depression in adults with diabetes. The study will also determine whether depressed diabetic patients who have successfully responded to sertraline (Zoloft) are more likely to have depression recur if the sertraline (Zoloft) is discontinued.

Detailed Description
-----------------
Part A: Prevention of Depression Recurrence in Diabetes To determine the efficacy of maintenance antidepressant medication in preventing or delaying recur-rence of major depression in diabetes. To determine the relationship of sustained depression remission to social, occupational, and global func-tioning, and to quality of life and compliance with diabetes treatment. To determine clinical features predictive of depression recurrence in diabetes. Part B. Longitudinal Study of the Interrelationship of Glycemic Control and Depression To determine the effects of depression remission and recurrence on glycemic control. To determine the efficacy of maintenance antidepressant medication in producing sustained benefits in glycemic control. To determine the interrelationship of daily mood with blood glucose and the effect of maintenance treatment on this relationship.

Official Title
-----------------
Preventing Depression Recurrence in Diabetes

Conditions
-----------------
Major Depression, Diabetes

Intervention / Treatment
-----------------
* Drug: sertraline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 18-80 Type 1 or Type 2 Diabetes Screen positive for depression Exclusion Criteria: Are pregnant or lactating Are known to be hypersensitive to the drug Have a recent history of myocardial infarction or unstable heart disease Have severe hepatic disease or renal impairment (serum creatinine > 3 mg/dl) The subset of patients with psychiatric disorders thought to affect management (e.g., schizophrenia, alcohol and drug dependence) will also be excluded from participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: sertraline|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
depression, diabetes mellitus, depression recurrence
A Development Plan of in Vitro Diagnostics of Immuno Magnetic Reduction Assay - A Rapid Etection Kit of Enterobacteraceae in Blood or Blood Culture

Study Overview
=================
Brief Summary
-----------------
This plan is to develop blood culture or to measure diagnostics of Immuno Magnetic Reduction assay in the first stage.

Official Title
-----------------
A Development Plan of in Vitro Diagnostics of Immuno Magnetic Reduction Assay - A Rapid Etection Kit of Enterobacteraceae in Blood or Blood Culture

Conditions
-----------------
Immuno Magnetic Reduction

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: emergency cases blood culture of positive and negative cases which storage in 4℃ every day Exclusion Criteria: not emergency cases of blood culture

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental Group<br> | |
| Control Group<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Return to Work and Functional Results of French Soldiers After Anterior Cruciate Ligament Reconstruction

Study Overview
=================
Brief Summary
-----------------
The return to work in the military population after surgical reconstruction of the anterior cruciate ligament (ACL) has been poorly investigated within the French armed forces. Only American studies are available and show that this surgery has a significant impact on the operational capacity of soldiers. ACL rupture is extremely frequent in active populations. This pathology has already been extensively explored in at-risk populations, particularly in sports. Most studies show that the resumption of sport is greatly affected by this pathology. Furthermore, an over-risk (10 times greater incidence of ACL rupture) in the military has been demonstrated.

Official Title
-----------------
Return to Work and Functional Results of French Soldiers After Anterior Cruciate Ligament Reconstruction

Conditions
-----------------
Anterior Cruciate Ligament Rupture

Intervention / Treatment
-----------------
* Other: On-line questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Military personnel who underwent first-line ACL reconstruction surgery between January 2014 and May 2019 Exclusion Criteria: People who have had ACL reconstruction surgery after initial failure People with a multiligamentous knee condition

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: On-line questionnaire|On-line questionnaire about working life, medical care, functional recovery, quality of life and psychological state.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of participants who regained their professional competence one year after anterior cruciate ligament (ACL) reconstruction surgery. |  | 1 year after anterior cruciate ligament (ACL) reconstruction surgery. |
Intra-Abdominal Pressure Effect on Intra-Abdominal Volume and Airway Pressures During Laparoscopy

Study Overview
=================
Brief Summary
-----------------
During pneumoperitoneum insufflation the insufflated gas increase intra-abdominal pressure. The generated pressure can lead to a different increase in volume depending on the abdominal cavity and patients' characteristics. The primary objective is to determine the relationship between intraabdominal pressure (IAP) and intraabdominal volume (IAV) during pneumoperitoneum insufflation. The secondary objective is to determine the rate of abdominal-thoracic transmission (ATT) assessing the correlation between IAP and respiratory driving pressure (ΔPRS).

Official Title
-----------------
Intra-Abdominal Pressure Effect on Intra-Abdominal Volume and Airway Pressures During Pneumoperitoneum Insufflation - a Patient-Level Meta-Analysis of Three Randomized Clinical Trials

Conditions
-----------------
Surgery, Pneumoperitoneum, Intra Abdominal Pressure

Intervention / Treatment
-----------------
* Other: Peritoneum insufflation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Enrolled one of the three studies (IPPCollapse I, II or III). underwent an initial insufflation procedure with a stepwise change in intraabdominal pressure to record Intraabdominal volume data from insufflation at 5 cmH2O of PEEP
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Global cohort<br>A global cohort is built merging data from three studies | Other: Peritoneum insufflation<br>* Before surgery pneumoperitoneum is established by insufflating gas into the abdomen. Intraabdominal pressure (IAP) is set to 15 mmHg for initial abdominal stretching and then decreased in a stepwise manner down until 8 mmHg.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Intraabdominal volume |  | During pneumoperitoneum insufflation before surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Driving pressure | This is the pressure that exert a stress on the respiratory system during mechanical ventilation. It is calculated by subtracting the positive endexpiratory pressure from plateau pressure | During pneumoperitoneum insufflation before surgery | 
| Plateau pressure | This is the pressure in the airway during the mechanical venitilation inspiratory pause time | During pneumoperitoneum insufflation before surgery |
An Evaluation of the Pharmacokinetics and Safety of LIPO-102 in Healthy Volunteers

Study Overview
=================
Brief Summary
-----------------
An Evaluation of the PK and Safety of LIPO-102 in Healthy Volunteers.

Conditions
-----------------
Subcutaneous Adipose Tissue Reduction

Intervention / Treatment
-----------------
* Drug: LIPO-102


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and non pregnant female 18-55 years old Sufficient abdominal fat for injections Signed informed consent Exclusion Criteria: Known hypersensitivity to study drugs Treatment with an investigational agent within 30 days before first dose

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LIPO-102<br> | Drug: LIPO-102<br>* LIPO-102<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety: Laboratory tests, medical exams |  | 4 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics |  | 24 hours |
Platelet Function With Various Storage Techniques

Study Overview
=================
Brief Summary
-----------------
Platelet function will be tested in individuals on antiplatelet medications to determine the optimal storage methodology.

Detailed Description
-----------------
Subjects will undergo administration of antiplatelet drugs and then will receive platelets stored in a variety of methods. Platelet function will be measured serially.

Official Title
-----------------
The Impact of Various Storage Techniques on Platelet Function

Conditions
-----------------
Platelet Dysfunction Due to Drugs

Intervention / Treatment
-----------------
* Biological: Infusion of Platelets
* Biological: Infusion of Platelets
* Biological: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Normal subjects Exclusion Criteria: Pre existing antiplatelet drugs

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Interventional Model Description: crossover study of various storage infusions techniques with each subject receiving various fluids aliquots.
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control (Placebo)<br>Subjects will receive infusion of placebo (saline). | Biological: Placebo<br>* Subjects will receive infusion placebo (saline).<br>* Other names: Placebo (Saline);|
| Active Comparator: Platelet storage routine<br>Subjects will receive infusion of platelets stored by routine method. | Biological: Infusion of Platelets<br>* Platelets will be stored using the routine platelet storage method. Subjects will receive infusion of platelets stored by routine storage method.<br>* Other names: Routine Storage Method;|
| Experimental: Platelet storage experimental<br>Subjects will receive infusion of platelets stored by a novel methodology. | Biological: Infusion of Platelets<br>* Platelets will be stored using novel, FDA approved, technique. Subjects will receive infusion of platelets stored by novel technique, routine storage, and placebo (saline).<br>* Other names: Novel Storage Methodology;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in platelet function | Frozen platelets will result in improvement in platelet function after transfusion. | 1 hour post-transfusion |
Point of Care Ketone Measurement in the Newborn

Study Overview
=================
Brief Summary
-----------------
Low blood sugar levels are common in babies after birth. This may be normal as babies can use other sources of energy. However if a baby does not produce these fuels the brain can be starved of energy and be damaged. Measurement of these fuels is not done as part of clinical practice in the newborn. The investigators aim to see whether at the same time as taking the blood sugar level from a heel prick these fuels can be measured in a small drop of blood. At the same time as blood needs to be taken for clinical reasons the study team will to take a drop of blood from 50 babies to see how good the point of care (POC) meters are compared to the laboratory at measuring these fuels. If accurate these POC meters could identifying those at risk from brain damage as well as prevent separation of mothers and babies who are establishing breast feeding.

Official Title
-----------------
Feasibility of the Use of Point of Care Technology to Measure Ketone and Lactate Levels in the Newborn at Risk From Hypoglycaemia Due to Impaired Perinatal Counter Regulation

Conditions
-----------------
Hypoglycaemia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Infants having blood samples taken for clinical management of glucose control Exclusion Criteria: -

Ages Eligible for Study
-----------------
Maximum Age: 1 Month

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Newborns at risk of hypoglycaemia<br>Measurement of ketones | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Measure of ketone levels between Point of care and laboratory assessment |  | Neonatal period up to 28 days of age | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Hypoglycaemia
rTMS for Apathy Clinical Trial

Study Overview
=================
Brief Summary
-----------------
Apathy is a common, early, and disabling symptom in dementias such as Alzheimer's disease (AD) and is characterized by lack of interest and enthusiasm. Both repetitive transcranial magnetic stimulation (rTMS), a form of non-invasive brain stimulation, and methylphenidate, a medication, have been shown to improve apathy. This pilot study will investigate rTMS as a treatment for apathy in AD in individuals receiving methylphenidate and individuals not receiving medication for apathy.

Official Title
-----------------
Repetitive Transcranial Magnetic Stimulation for Apathy Clinical Trial (REACT)

Conditions
-----------------
Alzheimer Disease, Apathy in Dementia

Intervention / Treatment
-----------------
* Device: rTMS
* Drug: methylphenidate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Alzheimer's disease or mixed Alzheimer's disease/vascular disease Apathy for at least 4 weeks Stable dose of medication (>4 weeks) that may affect cognition or behaviour Care partner who spends at least 10 hours a week with the subject Exclusion Criteria: Current major depressive episode Agitation, delusions, hallucination Medical contraindications to rTMS Currently taking an amphetamine product Central nervous system abnormalities, Tourette's syndrome, or motor tics Current participation in another clinical trial
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: rTMS + methylphenidate<br>repetitive transcranial magnetic stimulation (rTMS) and methylphenidate | Device: rTMS<br>* repetitive transcranial magnetic stimulation<br>Drug: methylphenidate<br>* methylphenidate<br>|
| Experimental: rTMS only<br>repetitive transcranial magnetic stimulation (rTMS) only | Device: rTMS<br>* repetitive transcranial magnetic stimulation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Apathy Evaluation Scale | Measure of apathy on a scale from 18 to 72 with a lower score indicating greater apathy | 2 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Apathy, Alzheimer's disease
Single Non-fasting OGTT Versus Fasting OGTT for Screening of Hyperglycaemia in Pregnancy (HIP)

Study Overview
=================
Brief Summary
-----------------
With the increasing prevalence of diabetes in pregnancy it is necessary to design a simple, sensitive, cost effective method for screening of hyperglycaemia in pregnancy specially in resource constrained settings. There is no universally agreed screening and diagnostic criteria to detect hyperglycemia in pregnancy. In present study, DIPSI (non-fasting OGTT) is compared with fasting oral glucose tolerance test (OGTT) to evaluate sensitivity and specificity of both methods in our population.

Official Title
-----------------
Single Non-fasting OGTT Versus Fasting OGTT for Screening of Hyperglycaemia in Pregnancy (HIP)

Conditions
-----------------
Diabetes in Pregnancy

Intervention / Treatment
-----------------
* Biological: Glucose


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All pregnant women Exclusion Criteria: Known diabetic
Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Single<br> | Biological: Glucose<br>* Oral Intake of Glucose<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Oral Glucose Tolerance | Measurement of Plasma Glucose after intake of 75 gram oral glucose | 2 hours |
Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane

Study Overview
=================
Brief Summary
-----------------
Comparison of the uremic toxin removal by haemodialysis either with a low flux or a new high flux cellulose triacetate membrane

Detailed Description
-----------------
Comparison of the uremic toxin removal by haemodialysis either with a low flux or a new high flux cellulose triacetate membrane

Official Title
-----------------
Uremic Toxin Removal With a New High Flux Cellulose Triacetate Membrane

Conditions
-----------------
Haemodialysis

Intervention / Treatment
-----------------
* Procedure: Haemodialysis with either low or high flux membranes


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chronic haemodialysis patient Serum albumin > 3.6 g/dl Exclusion Criteria: < 18 years

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Haemodialysis with either low or high flux membranes|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Concentration of uremic components after 3 weeks of haemodialysis |  |  |
Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

Study Overview
=================
Brief Summary
-----------------
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.

Detailed Description
-----------------
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular degeneration.

Official Title
-----------------
Triamcinolone Acetonide as an Adjunctive Treatment to Verteporfin Therapy in Neovascular Age-Related Macular Degeneration: Randomized Placebo-Controlled Clinical Trial.

Conditions
-----------------
Age-Related Macular Degeneration

Intervention / Treatment
-----------------
* Drug: Triamcinolone Acetonide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Individuals with predominantly classic, subfoveal CNV secondary to AMD. No previous PDT Treatment in study eye. Exclusion Criteria: CNV from conditions, other than AMD. Other disease that could be responsible for decreased vision.

Ages Eligible for Study
-----------------
Minimum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Triamcinolone Acetonide|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Changes in visual acuity from baseline. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in lesion characteristics from baseline. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
AMD, Triamcinolone, Macular Degeneration